Search Medical Condition
Please enter condition
Please choose location from dropdown

Tiberias, Israel Clinical Trials

A listing of Tiberias, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (15) clinical trials

Study of Collagen Membrane in Guided Bone Regeneration

Guided bone regeneration is a procedure used in dentistry for the reconstruction of osseous defects around teeth, dental implants, and prior to implant placement. The main function of the membrane barrier in GBR is to mechanically prevent the undesirable penetration of epithelial cells and fibroblasts to the bone defect area, ...

Phase

0.0 miles

Learn More »

Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty

Patients receiving BNP or nitroglycerin (IV) during the angioplasty procedure. 24 h after the procedure, vascular reactivity will be re-examined using the brachial artery flow-mediated dilatation study. Blood assays for ET-1, pro-BNP, and various inflammatory markers will be checked before and 24 h after the procedure. It is our hypothesis ...

Phase

0.0 miles

Learn More »

Treating Acute MI Patients With Aggrastat on Their Way to Hospital

Treating an AMI patient with ST elevation with Aggrastat in the ambulance on his or her way to the hospital.

Phase

0.0 miles

Learn More »

Effectiveness and Safety of Gordian Surgical's TroClose1200

Subjects that sign the Informed Consent Form will be evaluated for eligible for the study per eligibility criteria. Subject medical background and underlying disease requiring intervention will be taken at screening. Procedure will be scheduled. Subjects that will eventually, for any reason, will not be operated with the TroClose1200, will ...

Phase N/A

0.0 miles

Learn More »

A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

The drug being tested in this study is called ixazomib citrate. Ixazomib citrate is being tested to slow disease progression and improve overall survival in people who have newly diagnosed multiple myeloma (NDMM) who have had a major positive response to initial therapy and have not undergone stem cell transplantation ...

Phase

0.0 miles

Learn More »

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the ...

Phase

0.0 miles

Learn More »

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Na ve to Tumor Necrosis Factor (TNF) Inhibitors

This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to severe ulcerative colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Participants will be randomized in a 1:1 ratio ...

Phase

0.0 miles

Learn More »

UltraShape Power Device for Fat Reduction in Flanks

Eligible subjects will receive 3 bi-weekly treatments (2 weeks interval) with the UltraShape Power device according to the study protocol. One random flank will be treated with one pass or remained as a control (no treatment) while the second flank will be treated with multiple passes. Subjects will return for ...

Phase N/A

0.0 miles

Learn More »

Helicobacter Pylori Genome Project

Helicobacter pylori, a Gram-negative bacterium associated with a spectrum of benign and malignant gastric conditions, is one of the most genetically variable pathogens. Variations in a few genes have been associated with risk of inflammation and carcinogenesis, but to date no systematic study has evaluated the entire bacterial genome. We ...

Phase N/A

0.0 miles

Learn More »

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.

Phase

0.0 miles

Learn More »